Price Disclosure Reductions for 2020 April Cycle

Page last updated: 31 March 2020

This summary only includes medicines taking a price disclosure reduction on 1 April 2020. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

The Department is continuing to implement statutory pricing functions, including price disclosure reductions for the current and future cycles. Any queries or concerns should be sent to pricedisclosure@health.gov.au.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2020 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2020.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2019 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2019 will also take the reduction on 1 April 2020 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 23 December 2019

Indicative prices for 1 April 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2020Subscribe to PBS News to receive notice when they become available.

Final prices for 1 April 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2020.

It remains open for responsible persons to request a price increase. Further information about price increases can be found on the page Requesting a change to an existing price.

Excel version of 2020 April Cycle Outcomes Summary

 

Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)

Legal

Instrument

MoA

Legal Instrument Form

Average
AEMP
($)

WAPD
(%)
across a
drug/MoA

WADP -
potential
April '20
PBS Price (AEMP)
($) per
pharmaceutical
item

October '19
AEMP
($)

Percentage difference between October '19 and April '20  PBS prices (AEMP) (%) per
pharmaceutical item

Calculations based on:

OWAPD = all brand data

GWAPD = originator brand data removed for at least one pharmaceutical item

No originator brand determined

Does not meet 30 month clock

Applicable Unadjusted Price Reduction
10% or 30%

[Average AEMP minus WAPD = WADP]

 

[Difference between October '19
AEMP & WADP = % Difference]

abacavir with lamivudine

Oral

Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg

290.55

14.29%

249.03

290.55

14.29%

Does not meet 30 month clock

10

abacavir with lamivudine

Oral

Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg

290.55

14.29%

249.03

290.55

14.29%

Does not meet 30 month clock

10

acarbose

Oral

Tablet 100 mg

25.69

14.50%

21.96

25.69

14.52%

Does not meet 30 month clock

10

acarbose

Oral

Tablet 50 mg

18.14

14.50%

15.51

18.14

14.50%

Does not meet 30 month clock

10

aripiprazole

Oral

Tablet 10 mg

74.47

13.33%

64.54

74.47

13.33%

Does not meet 30 month clock

10

aripiprazole

Oral

Tablet 15 mg

105.68

13.33%

91.59

105.68

13.33%

Does not meet 30 month clock

10

aripiprazole

Oral

Tablet 20 mg

128.64

13.33%

111.49

128.64

13.33%

Does not meet 30 month clock

10

aripiprazole

Oral

Tablet 30 mg

156.76

13.33%

135.86

156.76

13.33%

Does not meet 30 month clock

10

atazanavir

Oral

Capsule 150 mg (as sulfate)

334.67

10.23%

300.43

334.67

10.23%

Does not meet 30 month clock

10

atazanavir

Oral

Capsule 200 mg (as sulfate)

446.24

10.23%

400.59

446.24

10.23%

Does not meet 30 month clock

10

atazanavir

Oral

Capsule 300 mg (as sulfate)

334.67

10.23%

300.43

334.67

10.23%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 10 mg (as hydrochloride)

41.65

13.17%

36.16

41.65

13.18%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 100 mg (as hydrochloride)

54.14

13.17%

47.01

54.14

13.17%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 18 mg (as hydrochloride)

41.65

13.17%

36.16

41.65

13.18%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 25 mg (as hydrochloride)

41.65

13.17%

36.16

41.65

13.18%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 40 mg (as hydrochloride)

41.65

13.17%

36.16

41.65

13.18%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 60 mg (as hydrochloride)

41.65

13.17%

36.16

41.65

13.18%

Does not meet 30 month clock

10

atomoxetine

Oral

Capsule 80 mg (as hydrochloride)

54.14

13.17%

47.01

54.14

13.17%

Does not meet 30 month clock

10

azacitidine

Injection

Powder for injection 100 mg

217.64

16.60%

181.51

217.64

16.60%

Does not meet 30 month clock

10

dexamethasone

Injection

Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL

5.69

38.39%

3.51

5.69

38.31%

No originator brand determined

30

dexamethasone

Injection

Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL

13.96

38.39%

8.60

13.96

38.40%

No originator brand determined

30

entecavir

Oral

Tablet 0.5 mg (as monohydrate)

168.85

28.19%

121.25

144.49

16.08%

Does not meet 30 month clock

10

entecavir

Oral

Tablet 1 mg (as monohydrate)

274.59

28.19%

197.18

234.98

16.09%

Does not meet 30 month clock

10

eplerenone

Oral

Tablet 25 mg

63.79

24.89%

47.91

63.79

24.89%

Does not meet 30 month clock

10

eplerenone

Oral

Tablet 50 mg

63.79

24.89%

47.91

63.79

24.89%

Does not meet 30 month clock

10

ezetimibe

Oral

Tablet 10 mg

29.44

40.34%

17.56

20.86

15.82%

Does not meet 30 month clock

10

ganciclovir

Injection

Powder for I.V. infusion 500 mg (as sodium)

200.67

21.08%

158.37

200.67

21.08%

Does not meet 30 month clock

10

imatinib

Oral

Capsule 100 mg (as mesilate)

851.25

51.11%

416.18

666.44

37.55%

Does not meet 30 month clock

10

imatinib

Oral

Capsule 400 mg (as mesilate)

1702.50

51.11%

832.35

1332.89

37.55%

Does not meet 30 month clock

10

imatinib

Oral

Tablet 100 mg (as mesilate)

851.25

51.11%

416.18

666.44

37.55%

Does not meet 30 month clock

10

imatinib

Oral

Tablet 400 mg (as mesilate)

1702.50

51.11%

832.35

1332.89

37.55%

Does not meet 30 month clock

10

lincomycin

Injection

Injection 600 mg (as hydrochloride monohydrate) in 2 mL

102.94

22.50%

79.78

92.49

13.74%

Does not meet 30 month clock

10

moxonidine

Oral

Tablet 200 micrograms

8.06

11.94%

7.10

8.06

11.91%

Does not meet 30 month clock

10

moxonidine

Oral

Tablet 400 micrograms

13.74

11.94%

12.10

13.74

11.94%

Does not meet 30 month clock

10

naloxone

Injection

Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe

34.36

19.17%

27.77

34.36

19.18%

Does not meet 30 month clock

10

naloxone

Injection

Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule

38.96

19.17%

31.49

38.96

19.17%

Does not meet 30 month clock

10

olmesartan

Oral

Tablet containing olmesartan medoxomil 20 mg

4.34

11.74%

3.83

4.34

11.75%

Does not meet 30 month clock

10

olmesartan

Oral

Tablet containing olmesartan medoxomil 40 mg

9.21

11.74%

8.13

9.21

11.73%

Does not meet 30 month clock

10

rizatriptan

Oral

Tablet (orally disintegrating) 10 mg (as benzoate)

4.57

10.44%

4.09

4.57

10.50%

Does not meet 30 month clock

10

rizatriptan

Oral

Wafer 10 mg (as benzoate)

4.57

10.44%

4.09

4.57

10.50%

Does not meet 30 month clock

10

rosuvastatin

Oral

Tablet 20 mg (as calcium)

7.31

30.04%

5.11

7.31

30.10%

GWAPD

30

rosuvastatin

Oral

Tablet 40 mg (as calcium)

10.43

30.04%

7.30

10.43

30.01%

GWAPD

30

rosuvastatin

Oral

Tablet 5 mg (as calcium)

3.50

30.04%

2.45

3.50

30.00%

GWAPD

30

tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

143.62

35.60%

92.49

143.62

35.60%

Does not meet 30 month clock

10

tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

143.62

35.60%

92.49

143.62

35.60%

Does not meet 30 month clock

10

tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg

143.62

35.60%

92.49

143.62

35.60%

Does not meet 30 month clock

10

tobramycin

Inhalation

Solution for inhalation 300 mg in 5 mL

938.45

25.30%

701.02

938.45

25.30%

Does not meet 30 month clock

10

valganciclovir

Oral

Tablet 450 mg (as hydrochloride)

1040.88

31.45%

713.52

902.27

20.92%

Does not meet 30 month clock

10

voriconazole

Oral

Tablet 200 mg

957.50

24.10%

726.74

957.50

24.10%

Does not meet 30 month clock

10

voriconazole

Oral

Tablet 50 mg

239.38

24.10%

181.69

239.38

24.10%

Does not meet 30 month clock

10

zoledronic acid

Injection

Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL

173.89

32.14%

118.00

132.37

10.86%

Does not meet 30 month clock

10

zoledronic acid

Injection

Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL vial

197.50

32.14%

134.02

197.50

32.14%

Does not meet 30 month clock

10

zoledronic acid

Injection

Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL

173.89

32.14%

118.00

132.37

10.86%

Does not meet 30 month clock

10

zoledronic acid

Injection

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

232.81

32.14%

157.98

177.21

10.85%

Does not meet 30 month clock

10